Rheumatoid Arthritis Diagnostics Market by Type (Assays, Instruments and Systems and Others) by Age Group (Below 30 Years, 30 Years to 50 Years and Above 50 Years) by Test Type (Serology (Anti-CCP Antibody Test, Rheumatoid Factor (RF)), Antinuclear Antibodies (ANAs), Acute Phase Reactants ((C-reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR)), Imaging Tests (X-ray, Magnetic Resonance Imaging (MRI), Ultrasound Imaging, Computed Tomography (CT) Scanning, Others)and Others) By End User (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 - 2029
Industry Trends
Global rheumatoid arthritis diagnostics market is expected to reach US$ 827.68 million by 2029, growing at a CAGR of 6.4% over the next eight years. Rising incidence and prevalence rate of rheumatoid arthritis and various types of autoimmune diseases across the worldwide has aided the overall market in the recent past and is expected to continue the similar trend over the forecast period.
Offering Insights
Assays captured the highest share in 2020. A rheumatoid factor test measures the amount of rheumatoid factor in your blood. Rheumatoid factors are proteins produced by the immune system that can attack healthy tissue in one’s body. Manufacturers/producers are focusing on the distribution agreement and partnership with local distributors and manufacturing companies to cater to the increasing need for rheumatoid arthritis diagnosis test kits across the world. Such a factor is expected to aid the overall rheumatoid arthritis diagnostics market over the forecast period. On the other hand, the instruments and systems segment is expected to witness the highest growth over the next eight years (2021 to 2029). Reduction in time and efforts required during testing is also one of the factors driving the growth of the global market.
Age Group Insights
The aforementioned disease is likely to occur in middle age, but young adults can get rheumatoid arthritis, too. According to the Arthritis Foundation, the average onset of rheumatoid arthritis is between the ages of 30 and 60 years old. The most represented age group among both women and men was the 55–69 years-old, with 634 (33%) women and 355 (39%) men. Such factors have assisted the growth of rheumatoid arthritis diagnostics market in the recent years and are expected to continue the same trend over the forecast period.
Regional Insights
North America accounted for the largest share in market; this growth can be attributed to rising demand from consumers in the United States. The United States region captured approximately more than 85% in 2020 and is expected to continue the similar trend over the forecast period. Approximately, 1.5 million Americans have rheumatoid arthritis. Women are about two to three times more likely to get rheumatoid arthritis than men. Hormones in both genders may play a role in either preventing or triggering it. RA generally starts between the ages of 30 and 60 in women and somewhat later in life in men. Introduction of novel biomarker test methods is expected to surge the growth of the rheumatoid arthritis diagnostics market in future years.
Rheumatoid Arthritis Diagnostics Market Revenue & Forecast, (US$ Million), 2021 – 2029
Competitive Landscape
The report provides both, qualitative and quantitative research on rheumatoid arthritis diagnostics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The major players operating in the rheumatoid arthritis diagnostics market include Abbott Diagnostics,ThermoFisher Scientific Antibodies Incorporated, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd. and other market participants.
Rheumatoid Arthritis Diagnostics Market:
By Offering
- Assays
- Instruments and Systems
- Others
By Age Group
- Below 30 Years
- 30 Years to 50 Years
- Above 50 Years
By Test Type
- Serology
- Anti-CCP Antibody Test
- Rheumatoid Factor (RF)
- Antinuclear Antibodies (ANAs)
- Uric Acid
- Acute Phase Reactants
- C-reactive Protein (CRP)
- Erythrocyte Sedimentation Rate (ESR)
- Imaging Tests
- X-ray
- Magnetic Resonance Imaging (MRI)
- Ultrasound Imaging
- Computed Tomography (CT) Scanning
- Others
- Others
By End Users
- Hospitals
- Diagnostics Centres
- Ambulatory Surgical Centers
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Rheumatoid Arthritis Diagnostics Market
6.
Market
Synopsis: Rheumatoid Arthritis
Diagnostics Market
7.
Rheumatoid
Arthritis Diagnostics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Rheumatoid Arthritis Diagnostics
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Rheumatoid Arthritis Diagnostics Market
7.6. Industry Gross Margin Overview
7.7. Porter’s Five Force Analysis
7.8. Impact of Covid-19 on Rheumatoid Arthritis
Diagnostics Market
8.
Global
Rheumatoid Arthritis Diagnostics Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn)
8.2. Global Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1. Assays
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market
Forecast, 2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Instruments and Systems
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Others
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Offering
9.
Global
Rheumatoid Arthritis Diagnostics Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
9.2.1. Below 30 Years
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. 30 Years to 50 Years
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3. Above 50 Years
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Age Group
10. Global Rheumatoid Arthritis Diagnostics
Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
10.2.1. Serology (Definition, Market Estimation and
Penetration, 2015 - 2020, Market Estimation (2015 - 2020), Market Forecast
(2021 - 2029), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Anti-CCP Antibody Test, Rheumatoid Factor (RF))
10.2.1.1. Anti-CCP Antibody Test
10.2.1.2. Rheumatoid Factor (RF)
10.2.2. Uric Acid
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Acute Phase Reactants (Definition, Market
Estimation and Penetration, 2015 - 2020, Market Estimation (2015 - 2020),
Market Forecast (2021 - 2029), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on C-reactive Protein (CRP), Erythrocyte Sedimentation
Rate (ESR))
10.2.3.1. C-reactive Protein (CRP)
10.2.3.2. Erythrocyte Sedimentation Rate (ESR)
10.2.4. Imaging Tests (Definition, Market Estimation
and Penetration, 2015 - 2020, Market Estimation (2015 - 2020), Market Forecast
(2021 - 2029), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on X-ray, Magnetic Resonance Imaging (MRI), Ultrasound Imaging,
Computed Tomography (CT) Scanning, Others)
10.2.4.1. X-ray
10.2.4.2. Magnetic Resonance Imaging (MRI)
10.2.4.3. Ultrasound Imaging
10.2.4.4. Computed Tomography (CT) Scanning
10.2.4.5. Others
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 -
2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 - 2020
10.2.5.5.1.2. Market Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2020
10.2.5.5.2.2. Market Forecast, 2021 - 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2020
10.2.5.5.3.2. Market Forecast, 2021 - 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2020
10.2.5.5.4.2. Market Forecast, 2021 - 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 - 2020
10.2.5.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Test Type
11. Global Rheumatoid Arthritis Diagnostics
Market Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1. Hospitals
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 -
2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 - 2020
11.2.1.5.1.2. Market Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2020
11.2.1.5.2.2. Market Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2020
11.2.1.5.3.2. Market Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2020
11.2.1.5.4.2. Market Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 - 2020
11.2.1.5.5.2. Market Forecast, 2021 - 2029
11.2.2. Diagnostics Centres
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 -
2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 - 2020
11.2.2.5.1.2. Market Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2020
11.2.2.5.2.2. Market Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2020
11.2.2.5.3.2. Market Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2020
11.2.2.5.4.2. Market Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 - 2020
11.2.2.5.5.2. Market Forecast, 2021 - 2029
11.2.3. Ambulatory Surgical Centers
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 -
2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015 - 2020
11.2.3.5.1.2. Market Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2020
11.2.3.5.2.2. Market Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2020
11.2.3.5.3.2. Market Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2020
11.2.3.5.4.2. Market Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015 - 2020
11.2.3.5.5.2. Market Forecast, 2021 - 2029
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 -
2020
11.2.4.3. Market Forecast, 2021 - 2029
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market Estimation, 2015 - 2020
11.2.4.5.1.2. Market Forecast, 2021 - 2029
11.2.4.5.2. Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2020
11.2.4.5.2.2. Market Forecast, 2021 - 2029
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2020
11.2.4.5.3.2. Market Forecast, 2021 - 2029
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2020
11.2.4.5.4.2. Market Forecast, 2021 - 2029
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market Estimation, 2015 - 2020
11.2.4.5.5.2. Market Forecast, 2021 - 2029
11.3. Key Segment for Channeling Investments
11.3.1. By End Users
12. North America Rheumatoid Arthritis
Diagnostics Market Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn)
12.2. North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
12.2.1. Assays
12.2.2. Instruments and Systems
12.2.3. Others
12.3. North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
12.3.1. Below 30 Years
12.3.2. 30 Years to 50 Years
12.3.3. Above 50 Years
12.4. North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
12.4.1. Serology
12.4.1.1. Anti-CCP Antibody Test
12.4.1.2. Rheumatoid Factor (RF)
12.4.2. Uric Acid
12.4.3. Acute Phase Reactants
12.4.3.1. C-reactive Protein (CRP)
12.4.3.2. Erythrocyte Sedimentation Rate (ESR)
12.4.4. Imaging Tests
12.4.4.1. X-ray
12.4.4.2. Magnetic Resonance Imaging (MRI)
12.4.4.3. Ultrasound Imaging
12.4.4.4. Computed Tomography (CT) Scanning
12.4.4.5. Others
12.4.5. Others
12.5. North America Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.1. Hospitals
12.5.2. Diagnostics Centres
12.5.3. Ambulatory Surgical Centers
12.5.4. Others
12.6. North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offering
12.6.1.1.1. Assays
12.6.1.1.2. Instruments and Systems
12.6.1.1.3. Others
12.6.1.2. U.S Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
12.6.1.2.1. Below 30 Years
12.6.1.2.2. 30 Years to 50 Years
12.6.1.2.3. Above 50 Years
12.6.1.3. U.S Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.6.1.3.1. Serology
12.6.1.3.1.1. Anti-CCP Antibody Test
12.6.1.3.1.2. Rheumatoid Factor (RF)
12.6.1.3.2. Uric Acid
12.6.1.3.3. Acute Phase Reactants
12.6.1.3.3.1. C-reactive Protein (CRP)
12.6.1.3.3.2. Erythrocyte Sedimentation Rate (ESR)
12.6.1.3.4. Imaging Tests
12.6.1.3.4.1. X-ray
12.6.1.3.4.2. Magnetic Resonance Imaging (MRI)
12.6.1.3.4.3. Ultrasound Imaging
12.6.1.3.4.4. Computed Tomography (CT) Scanning
12.6.1.3.4.5. Others
12.6.1.3.5. Others
12.6.1.4. U.S Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End Users
12.6.1.4.1. Hospitals
12.6.1.4.2. Diagnostics Centres
12.6.1.4.3. Ambulatory Surgical Centers
12.6.1.4.4. Others
12.6.2. Canada
12.6.2.1. Canada Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.2.1.1. Assays
12.6.2.1.2. Instruments and Systems
12.6.2.1.3. Others
12.6.2.2. Canada Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
12.6.2.2.1. Below 30 Years
12.6.2.2.2. 30 Years to 50 Years
12.6.2.2.3. Above 50 Years
12.6.2.3. Canada Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
12.6.2.3.1. Serology
12.6.2.3.1.1. Anti-CCP Antibody Test
12.6.2.3.1.2. Rheumatoid Factor (RF)
12.6.2.3.2. Uric Acid
12.6.2.3.3. Acute Phase Reactants
12.6.2.3.3.1. C-reactive Protein (CRP)
12.6.2.3.3.2. Erythrocyte Sedimentation Rate (ESR)
12.6.2.3.4. Imaging Tests
12.6.2.3.4.1. X-ray
12.6.2.3.4.2. Magnetic Resonance Imaging (MRI)
12.6.2.3.4.3. Ultrasound Imaging
12.6.2.3.4.4. Computed Tomography (CT) Scanning
12.6.2.3.4.5. Others
12.6.2.3.5. Others
12.6.2.4. Canada Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.2.4.1. Hospitals
12.6.2.4.2. Diagnostics Centres
12.6.2.4.3. Ambulatory Surgical Centers
12.6.2.4.4. Others
12.6.3. Mexico
12.6.3.1. Mexico Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.3.1.1. Assays
12.6.3.1.2. Instruments and Systems
12.6.3.1.3. Others
12.6.3.2. Mexico Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
12.6.3.2.1. Below 30 Years
12.6.3.2.2. 30 Years to 50 Years
12.6.3.2.3. Above 50 Years
12.6.3.3. Mexico Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
12.6.3.3.1. Serology
12.6.3.3.1.1. Anti-CCP Antibody Test
12.6.3.3.1.2. Rheumatoid Factor (RF)
12.6.3.3.2. Uric Acid
12.6.3.3.3. Acute Phase Reactants
12.6.3.3.3.1. C-reactive Protein (CRP)
12.6.3.3.3.2. Erythrocyte Sedimentation Rate (ESR)
12.6.3.3.4. Imaging Tests
12.6.3.3.4.1. X-ray
12.6.3.3.4.2. Magnetic Resonance Imaging (MRI)
12.6.3.3.4.3. Ultrasound Imaging
12.6.3.3.4.4. Computed Tomography (CT) Scanning
12.6.3.3.4.5. Others
12.6.3.3.5. Others
12.6.3.4. Mexico Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.3.4.1. Hospitals
12.6.3.4.2. Diagnostics Centres
12.6.3.4.3. Ambulatory Surgical Centers
12.6.3.4.4. Others
12.6.4. Rest of North America
12.6.4.1. Rest of North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.4.1.1. Assays
12.6.4.1.2. Instruments and Systems
12.6.4.1.3. Others
12.6.4.2. Rest of North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
12.6.4.2.1. Below 30 Years
12.6.4.2.2. 30 Years to 50 Years
12.6.4.2.3. Above 50 Years
12.6.4.3. Rest of North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
12.6.4.3.1. Serology
12.6.4.3.1.1. Anti-CCP Antibody Test
12.6.4.3.1.2. Rheumatoid Factor (RF)
12.6.4.3.2. Uric Acid
12.6.4.3.3. Acute Phase Reactants
12.6.4.3.3.1. C-reactive Protein (CRP)
12.6.4.3.3.2. Erythrocyte Sedimentation Rate (ESR)
12.6.4.3.4. Imaging Tests
12.6.4.3.4.1. X-ray
12.6.4.3.4.2. Magnetic Resonance Imaging (MRI)
12.6.4.3.4.3. Ultrasound Imaging
12.6.4.3.4.4. Computed Tomography (CT) Scanning
12.6.4.3.4.5. Others
12.6.4.3.5. Others
12.6.4.4. Rest of North America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals
12.6.4.4.2. Diagnostics Centres
12.6.4.4.3. Ambulatory Surgical Centers
12.6.4.4.4. Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Offering
12.7.3. By Age Group
12.7.4. By Test Type
12.7.5. By End Users
13. Europe Rheumatoid Arthritis Diagnostics
Market Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn)
13.2. Europe Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
13.2.1. Assays
13.2.2. Instruments and Systems
13.2.3. Others
13.3. Europe Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
13.3.1. Below 30 Years
13.3.2. 30 Years to 50 Years
13.3.3. Above 50 Years
13.4. Europe Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.4.1. Serology
13.4.1.1. Anti-CCP Antibody Test
13.4.1.2. Rheumatoid Factor (RF)
13.4.2. Uric Acid
13.4.3. Acute Phase Reactants
13.4.3.1. C-reactive Protein (CRP)
13.4.3.2. Erythrocyte Sedimentation Rate (ESR)
13.4.4. Imaging Tests
13.4.4.1. X-ray
13.4.4.2. Magnetic Resonance Imaging (MRI)
13.4.4.3. Ultrasound Imaging
13.4.4.4. Computed Tomography (CT) Scanning
13.4.4.5. Others
13.4.5. Others
13.5. Europe Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1. Hospitals
13.5.2. Diagnostics Centres
13.5.3. Ambulatory Surgical Centers
13.5.4. Others
13.6. Europe Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.1.1.1. Assays
13.6.1.1.2. Instruments and Systems
13.6.1.1.3. Others
13.6.1.2. France Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.1.2.1. Below 30 Years
13.6.1.2.2. 30 Years to 50 Years
13.6.1.2.3. Above 50 Years
13.6.1.3. France Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.6.1.3.1. Serology
13.6.1.3.1.1. Anti-CCP Antibody Test
13.6.1.3.1.2. Rheumatoid Factor (RF)
13.6.1.3.2. Uric Acid
13.6.1.3.3. Acute Phase Reactants
13.6.1.3.3.1. C-reactive Protein (CRP)
13.6.1.3.3.2. Erythrocyte Sedimentation Rate (ESR)
13.6.1.3.4. Imaging Tests
13.6.1.3.4.1. X-ray
13.6.1.3.4.2. Magnetic Resonance Imaging (MRI)
13.6.1.3.4.3. Ultrasound Imaging
13.6.1.3.4.4. Computed Tomography (CT) Scanning
13.6.1.3.4.5. Others
13.6.1.3.5. Others
13.6.1.4. France Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.4.1. Hospitals
13.6.1.4.2. Diagnostics Centres
13.6.1.4.3. Ambulatory Surgical Centers
13.6.1.4.4. Others
13.6.2. The UK
13.6.2.1. The UK Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.2.1.1. Assays
13.6.2.1.2. Instruments and Systems
13.6.2.1.3. Others
13.6.2.2. The UK Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.2.2.1. Below 30 Years
13.6.2.2.2. 30 Years to 50 Years
13.6.2.2.3. Above 50 Years
13.6.2.3. The UK Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.6.2.3.1. Serology
13.6.2.3.1.1. Anti-CCP Antibody Test
13.6.2.3.1.2. Rheumatoid Factor (RF)
13.6.2.3.2. Uric Acid
13.6.2.3.3. Acute Phase Reactants
13.6.2.3.3.1. C-reactive Protein (CRP)
13.6.2.3.3.2. Erythrocyte Sedimentation Rate (ESR)
13.6.2.3.4. Imaging Tests
13.6.2.3.4.1. X-ray
13.6.2.3.4.2. Magnetic Resonance Imaging (MRI)
13.6.2.3.4.3. Ultrasound Imaging
13.6.2.3.4.4. Computed Tomography (CT) Scanning
13.6.2.3.4.5. Others
13.6.2.3.5. Others
13.6.2.4. The UK Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.2.4.1. Hospitals
13.6.2.4.2. Diagnostics Centres
13.6.2.4.3. Ambulatory Surgical Centers
13.6.2.4.4. Others
13.6.3. Spain
13.6.3.1. Spain Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offering
13.6.3.1.1. Assays
13.6.3.1.2. Instruments and Systems
13.6.3.1.3. Others
13.6.3.2. Spain Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
13.6.3.2.1. Below 30 Years
13.6.3.2.2. 30 Years to 50 Years
13.6.3.2.3. Above 50 Years
13.6.3.3. Spain Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Test Type
13.6.3.3.1. Serology
13.6.3.3.1.1. Anti-CCP Antibody Test
13.6.3.3.1.2. Rheumatoid Factor (RF)
13.6.3.3.2. Uric Acid
13.6.3.3.3. Acute Phase Reactants
13.6.3.3.3.1. C-reactive Protein (CRP)
13.6.3.3.3.2. Erythrocyte Sedimentation Rate (ESR)
13.6.3.3.4. Imaging Tests
13.6.3.3.4.1. X-ray
13.6.3.3.4.2. Magnetic Resonance Imaging (MRI)
13.6.3.3.4.3. Ultrasound Imaging
13.6.3.3.4.4. Computed Tomography (CT) Scanning
13.6.3.3.4.5. Others
13.6.3.3.5. Others
13.6.3.4. Spain Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.3.4.1. Hospitals
13.6.3.4.2. Diagnostics Centres
13.6.3.4.3. Ambulatory Surgical Centers
13.6.3.4.4. Others
13.6.4. Germany
13.6.4.1. Germany Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.4.1.1. Assays
13.6.4.1.2. Instruments and Systems
13.6.4.1.3. Others
13.6.4.2. Germany Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
13.6.4.2.1. Below 30 Years
13.6.4.2.2. 30 Years to 50 Years
13.6.4.2.3. Above 50 Years
13.6.4.3. Germany Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.6.4.3.1. Serology
13.6.4.3.1.1. Anti-CCP Antibody Test
13.6.4.3.1.2. Rheumatoid Factor (RF)
13.6.4.3.2. Uric Acid
13.6.4.3.3. Acute Phase Reactants
13.6.4.3.3.1. C-reactive Protein (CRP)
13.6.4.3.3.2. Erythrocyte Sedimentation Rate (ESR)
13.6.4.3.4. Imaging Tests
13.6.4.3.4.1. X-ray
13.6.4.3.4.2. Magnetic Resonance Imaging (MRI)
13.6.4.3.4.3. Ultrasound Imaging
13.6.4.3.4.4. Computed Tomography (CT) Scanning
13.6.4.3.4.5. Others
13.6.4.3.5. Others
13.6.4.4. Germany Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.4.4.1. Hospitals
13.6.4.4.2. Diagnostics Centres
13.6.4.4.3. Ambulatory Surgical Centers
13.6.4.4.4. Others
13.6.5. Italy
13.6.5.1. Italy Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offering
13.6.5.1.1. Assays
13.6.5.1.2. Instruments and Systems
13.6.5.1.3. Others
13.6.5.2. Italy Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
13.6.5.2.1. Below 30 Years
13.6.5.2.2. 30 Years to 50 Years
13.6.5.2.3. Above 50 Years
13.6.5.3. Italy Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Test Type
13.6.5.3.1. Serology
13.6.5.3.1.1. Anti-CCP Antibody Test
13.6.5.3.1.2. Rheumatoid Factor (RF)
13.6.5.3.2. Uric Acid
13.6.5.3.3. Acute Phase Reactants
13.6.5.3.3.1. C-reactive Protein (CRP)
13.6.5.3.3.2. Erythrocyte Sedimentation Rate (ESR)
13.6.5.3.4. Imaging Tests
13.6.5.3.4.1. X-ray
13.6.5.3.4.2. Magnetic Resonance Imaging (MRI)
13.6.5.3.4.3. Ultrasound Imaging
13.6.5.3.4.4. Computed Tomography (CT) Scanning
13.6.5.3.4.5. Others
13.6.5.3.5. Others
13.6.5.4. Italy Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.5.4.1. Hospitals
13.6.5.4.2. Diagnostics Centres
13.6.5.4.3. Ambulatory Surgical Centers
13.6.5.4.4. Others
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.6.1.1. Assays
13.6.6.1.2. Instruments and Systems
13.6.6.1.3. Others
13.6.6.2. Nordic Countries Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.6.2.1. Below 30 Years
13.6.6.2.2. 30 Years to 50 Years
13.6.6.2.3. Above 50 Years
13.6.6.3. Nordic Countries Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
13.6.6.3.1. Serology
13.6.6.3.1.1. Anti-CCP Antibody Test
13.6.6.3.1.2. Rheumatoid Factor (RF)
13.6.6.3.2. Uric Acid
13.6.6.3.3. Acute Phase Reactants
13.6.6.3.3.1. C-reactive Protein (CRP)
13.6.6.3.3.2. Erythrocyte Sedimentation Rate (ESR)
13.6.6.3.4. Imaging Tests
13.6.6.3.4.1. X-ray
13.6.6.3.4.2. Magnetic Resonance Imaging (MRI)
13.6.6.3.4.3. Ultrasound Imaging
13.6.6.3.4.4. Computed Tomography (CT) Scanning
13.6.6.3.4.5. Others
13.6.6.3.5. Others
13.6.6.4. Nordic Countries Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1. Hospitals
13.6.6.4.2. Diagnostics Centres
13.6.6.4.3. Ambulatory Surgical Centers
13.6.6.4.4. Others
13.6.6.5. Nordic Countries Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.7.1.1. Assays
13.6.7.1.2. Instruments and Systems
13.6.7.1.3. Others
13.6.7.2. Benelux Union Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.7.2.1. Below 30 Years
13.6.7.2.2. 30 Years to 50 Years
13.6.7.2.3. Above 50 Years
13.6.7.3. Benelux Union Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
13.6.7.3.1. Serology
13.6.7.3.1.1. Anti-CCP Antibody Test
13.6.7.3.1.2. Rheumatoid Factor (RF)
13.6.7.3.2. Uric Acid
13.6.7.3.3. Acute Phase Reactants
13.6.7.3.3.1. C-reactive Protein (CRP)
13.6.7.3.3.2. Erythrocyte Sedimentation Rate (ESR)
13.6.7.3.4. Imaging Tests
13.6.7.3.4.1. X-ray
13.6.7.3.4.2. Magnetic Resonance Imaging (MRI)
13.6.7.3.4.3. Ultrasound Imaging
13.6.7.3.4.4. Computed Tomography (CT) Scanning
13.6.7.3.4.5. Others
13.6.7.3.5. Others
13.6.7.4. Benelux Union Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.4.1. Hospitals
13.6.7.4.2. Diagnostics Centres
13.6.7.4.3. Ambulatory Surgical Centers
13.6.7.4.4. Others
13.6.7.5. Benelux Union Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.8.1.1. Assays
13.6.8.1.2. Instruments and Systems
13.6.8.1.3. Others
13.6.8.2. Rest of Europe Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.8.2.1. Below 30 Years
13.6.8.2.2. 30 Years to 50 Years
13.6.8.2.3. Above 50 Years
13.6.8.3. Rest of Europe Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
13.6.8.3.1. Serology
13.6.8.3.1.1. Anti-CCP Antibody Test
13.6.8.3.1.2. Rheumatoid Factor (RF)
13.6.8.3.2. Uric Acid
13.6.8.3.3. Acute Phase Reactants
13.6.8.3.3.1. C-reactive Protein (CRP)
13.6.8.3.3.2. Erythrocyte Sedimentation Rate (ESR)
13.6.8.3.4. Imaging Tests
13.6.8.3.4.1. X-ray
13.6.8.3.4.2. Magnetic Resonance Imaging (MRI)
13.6.8.3.4.3. Ultrasound Imaging
13.6.8.3.4.4. Computed Tomography (CT) Scanning
13.6.8.3.4.5. Others
13.6.8.3.5. Others
13.6.8.4. Rest of Europe Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1. Hospitals
13.6.8.4.2. Diagnostics Centres
13.6.8.4.3. Ambulatory Surgical Centers
13.6.8.4.4. Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Offering
13.7.3. By Age Group
13.7.4. By Test Type
13.7.5. By End Users
14. Asia Pacific Rheumatoid Arthritis
Diagnostics Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia Pacific Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn)
14.2. Asia Pacific Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
14.2.1. Assays
14.2.2. Instruments and Systems
14.2.3. Others
14.3. Asia Pacific Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
14.3.1. Below 30 Years
14.3.2. 30 Years to 50 Years
14.3.3. Above 50 Years
14.4. Asia Pacific Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
14.4.1. Serology
14.4.1.1. Anti-CCP Antibody Test
14.4.1.2. Rheumatoid Factor (RF)
14.4.2. Uric Acid
14.4.3. Acute Phase Reactants
14.4.3.1. C-reactive Protein (CRP)
14.4.3.2. Erythrocyte Sedimentation Rate (ESR)
14.4.4. Imaging Tests
14.4.4.1. X-ray
14.4.4.2. Magnetic Resonance Imaging (MRI)
14.4.4.3. Ultrasound Imaging
14.4.4.4. Computed Tomography (CT) Scanning
14.4.4.5. Others
14.4.5. Others
14.5. Asia Pacific Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1. Hospitals
14.5.2. Diagnostics Centres
14.5.3. Ambulatory Surgical Centers
14.5.4. Others
14.6. Asia Pacific Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offering
14.6.1.1.1. Assays
14.6.1.1.2. Instruments and Systems
14.6.1.1.3. Others
14.6.1.2. China Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
14.6.1.2.1. Below 30 Years
14.6.1.2.2. 30 Years to 50 Years
14.6.1.2.3. Above 50 Years
14.6.1.3. China Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Test Type
14.6.1.3.1. Serology
14.6.1.3.1.1. Anti-CCP Antibody Test
14.6.1.3.1.2. Rheumatoid Factor (RF)
14.6.1.3.2. Uric Acid
14.6.1.3.3. Acute Phase Reactants
14.6.1.3.3.1. C-reactive Protein (CRP)
14.6.1.3.3.2. Erythrocyte Sedimentation Rate (ESR)
14.6.1.3.4. Imaging Tests
14.6.1.3.4.1. X-ray
14.6.1.3.4.2. Magnetic Resonance Imaging (MRI)
14.6.1.3.4.3. Ultrasound Imaging
14.6.1.3.4.4. Computed Tomography (CT) Scanning
14.6.1.3.4.5. Others
14.6.1.3.5. Others
14.6.1.4. China Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.4.1. Hospitals
14.6.1.4.2. Diagnostics Centres
14.6.1.4.3. Ambulatory Surgical Centers
14.6.1.4.4. Others
14.6.2. Japan
14.6.2.1. Japan Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offering
14.6.2.1.1. Assays
14.6.2.1.2. Instruments and Systems
14.6.2.1.3. Others
14.6.2.2. Japan Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
14.6.2.2.1. Below 30 Years
14.6.2.2.2. 30 Years to 50 Years
14.6.2.2.3. Above 50 Years
14.6.2.3. Japan Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Test Type
14.6.2.3.1. Serology
14.6.2.3.1.1. Anti-CCP Antibody Test
14.6.2.3.1.2. Rheumatoid Factor (RF)
14.6.2.3.2. Uric Acid
14.6.2.3.3. Acute Phase Reactants
14.6.2.3.3.1. C-reactive Protein (CRP)
14.6.2.3.3.2. Erythrocyte Sedimentation Rate (ESR)
14.6.2.3.4. Imaging Tests
14.6.2.3.4.1. X-ray
14.6.2.3.4.2. Magnetic Resonance Imaging (MRI)
14.6.2.3.4.3. Ultrasound Imaging
14.6.2.3.4.4. Computed Tomography (CT) Scanning
14.6.2.3.4.5. Others
14.6.2.3.5. Others
14.6.2.4. Japan Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.2.4.1. Hospitals
14.6.2.4.2. Diagnostics Centres
14.6.2.4.3. Ambulatory Surgical Centers
14.6.2.4.4. Others
14.6.3. India
14.6.3.1. India Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offering
14.6.3.1.1. Assays
14.6.3.1.2. Instruments and Systems
14.6.3.1.3. Others
14.6.3.2. India Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
14.6.3.2.1. Below 30 Years
14.6.3.2.2. 30 Years to 50 Years
14.6.3.2.3. Above 50 Years
14.6.3.3. India Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Test Type
14.6.3.3.1. Serology
14.6.3.3.1.1. Anti-CCP Antibody Test
14.6.3.3.1.2. Rheumatoid Factor (RF)
14.6.3.3.2. Uric Acid
14.6.3.3.3. Acute Phase Reactants
14.6.3.3.3.1. C-reactive Protein (CRP)
14.6.3.3.3.2. Erythrocyte Sedimentation Rate (ESR)
14.6.3.3.4. Imaging Tests
14.6.3.3.4.1. X-ray
14.6.3.3.4.2. Magnetic Resonance Imaging (MRI)
14.6.3.3.4.3. Ultrasound Imaging
14.6.3.3.4.4. Computed Tomography (CT) Scanning
14.6.3.3.4.5. Others
14.6.3.3.5. Others
14.6.3.4. India Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.3.4.1. Hospitals
14.6.3.4.2. Diagnostics Centres
14.6.3.4.3. Ambulatory Surgical Centers
14.6.3.4.4. Others
14.6.4. New Zealand
14.6.4.1. New Zealand Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.4.1.1. Assays
14.6.4.1.2. Instruments and Systems
14.6.4.1.3. Others
14.6.4.2. New Zealand Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.4.2.1. Below 30 Years
14.6.4.2.2. 30 Years to 50 Years
14.6.4.2.3. Above 50 Years
14.6.4.3. New Zealand Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
14.6.4.3.1. Serology
14.6.4.3.1.1. Anti-CCP Antibody Test
14.6.4.3.1.2. Rheumatoid Factor (RF)
14.6.4.3.2. Uric Acid
14.6.4.3.3. Acute Phase Reactants
14.6.4.3.3.1. C-reactive Protein (CRP)
14.6.4.3.3.2. Erythrocyte Sedimentation Rate (ESR)
14.6.4.3.4. Imaging Tests
14.6.4.3.4.1. X-ray
14.6.4.3.4.2. Magnetic Resonance Imaging (MRI)
14.6.4.3.4.3. Ultrasound Imaging
14.6.4.3.4.4. Computed Tomography (CT) Scanning
14.6.4.3.4.5. Others
14.6.4.3.5. Others
14.6.4.4. New Zealand Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.4.4.1. Hospitals
14.6.4.4.2. Diagnostics Centres
14.6.4.4.3. Ambulatory Surgical Centers
14.6.4.4.4. Others
14.6.5. Australia
14.6.5.1. Australia Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.5.1.1. Assays
14.6.5.1.2. Instruments and Systems
14.6.5.1.3. Others
14.6.5.2. Australia Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.5.2.1. Below 30 Years
14.6.5.2.2. 30 Years to 50 Years
14.6.5.2.3. Above 50 Years
14.6.5.3. Australia Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
14.6.5.3.1. Serology
14.6.5.3.1.1. Anti-CCP Antibody Test
14.6.5.3.1.2. Rheumatoid Factor (RF)
14.6.5.3.2. Uric Acid
14.6.5.3.3. Acute Phase Reactants
14.6.5.3.3.1. C-reactive Protein (CRP)
14.6.5.3.3.2. Erythrocyte Sedimentation Rate (ESR)
14.6.5.3.4. Imaging Tests
14.6.5.3.4.1. X-ray
14.6.5.3.4.2. Magnetic Resonance Imaging (MRI)
14.6.5.3.4.3. Ultrasound Imaging
14.6.5.3.4.4. Computed Tomography (CT) Scanning
14.6.5.3.4.5. Others
14.6.5.3.5. Others
14.6.5.4. Australia Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.5.4.1. Hospitals
14.6.5.4.2. Diagnostics Centres
14.6.5.4.3. Ambulatory Surgical Centers
14.6.5.4.4. Others
14.6.6. South Korea
14.6.6.1. South Korea Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.6.1.1. Assays
14.6.6.1.2. Instruments and Systems
14.6.6.1.3. Others
14.6.6.2. South Korea Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.6.2.1. Below 30 Years
14.6.6.2.2. 30 Years to 50 Years
14.6.6.2.3. Above 50 Years
14.6.6.3. South Korea Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
14.6.6.3.1. Serology
14.6.6.3.1.1. Anti-CCP Antibody Test
14.6.6.3.1.2. Rheumatoid Factor (RF)
14.6.6.3.2. Uric Acid
14.6.6.3.3. Acute Phase Reactants
14.6.6.3.3.1. C-reactive Protein (CRP)
14.6.6.3.3.2. Erythrocyte Sedimentation Rate (ESR)
14.6.6.3.4. Imaging Tests
14.6.6.3.4.1. X-ray
14.6.6.3.4.2. Magnetic Resonance Imaging (MRI)
14.6.6.3.4.3. Ultrasound Imaging
14.6.6.3.4.4. Computed Tomography (CT) Scanning
14.6.6.3.4.5. Others
14.6.6.3.5. Others
14.6.6.4. South Korea Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.6.4.1. Hospitals
14.6.6.4.2. Diagnostics Centres
14.6.6.4.3. Ambulatory Surgical Centers
14.6.6.4.4. Others
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.7.1.1. Assays
14.6.7.1.2. Instruments and Systems
14.6.7.1.3. Others
14.6.7.2. Southeast Asia Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.7.2.1. Below 30 Years
14.6.7.2.2. 30 Years to 50 Years
14.6.7.2.3. Above 50 Years
14.6.7.3. Southeast Asia Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
14.6.7.3.1. Serology
14.6.7.3.1.1. Anti-CCP Antibody Test
14.6.7.3.1.2. Rheumatoid Factor (RF)
14.6.7.3.2. Uric Acid
14.6.7.3.3. Acute Phase Reactants
14.6.7.3.3.1. C-reactive Protein (CRP)
14.6.7.3.3.2. Erythrocyte Sedimentation Rate (ESR)
14.6.7.3.4. Imaging Tests
14.6.7.3.4.1. X-ray
14.6.7.3.4.2. Magnetic Resonance Imaging (MRI)
14.6.7.3.4.3. Ultrasound Imaging
14.6.7.3.4.4. Computed Tomography (CT) Scanning
14.6.7.3.4.5. Others
14.6.7.3.5. Others
14.6.7.4. Southeast Asia Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.4.1. Hospitals
14.6.7.4.2. Diagnostics Centres
14.6.7.4.3. Ambulatory Surgical Centers
14.6.7.4.4. Others
14.6.7.5. Southeast Asia Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.8.1.1. Assays
14.6.8.1.2. Instruments and Systems
14.6.8.1.3. Others
14.6.8.2. Rest of Asia Pacific Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.8.2.1. Below 30 Years
14.6.8.2.2. 30 Years to 50 Years
14.6.8.2.3. Above 50 Years
14.6.8.3. Rest of Asia Pacific Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
14.6.8.3.1. Serology
14.6.8.3.1.1. Anti-CCP Antibody Test
14.6.8.3.1.2. Rheumatoid Factor (RF)
14.6.8.3.2. Uric Acid
14.6.8.3.3. Acute Phase Reactants
14.6.8.3.3.1. C-reactive Protein (CRP)
14.6.8.3.3.2. Erythrocyte Sedimentation Rate (ESR)
14.6.8.3.4. Imaging Tests
14.6.8.3.4.1. X-ray
14.6.8.3.4.2. Magnetic Resonance Imaging (MRI)
14.6.8.3.4.3. Ultrasound Imaging
14.6.8.3.4.4. Computed Tomography (CT) Scanning
14.6.8.3.4.5. Others
14.6.8.3.5. Others
14.6.8.4. Rest of Asia Pacific Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals
14.6.8.4.2. Diagnostics Centres
14.6.8.4.3. Ambulatory Surgical Centers
14.6.8.4.4. Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Offering
14.7.3. By Age Group
14.7.4. By Test Type
14.7.5. By End Users
15. Middle East and Africa Rheumatoid Arthritis
Diagnostics Market Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle East and Africa Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn)
15.2. Middle East and Africa Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
15.2.1. Assays
15.2.2. Instruments and Systems
15.2.3. Others
15.3. Middle East and Africa Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
15.3.1. Below 30 Years
15.3.2. 30 Years to 50 Years
15.3.3. Above 50 Years
15.4. Middle East and Africa Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
15.4.1. Serology
15.4.1.1. Anti-CCP Antibody Test
15.4.1.2. Rheumatoid Factor (RF)
15.4.2. Uric Acid
15.4.3. Acute Phase Reactants
15.4.3.1. C-reactive Protein (CRP)
15.4.3.2. Erythrocyte Sedimentation Rate (ESR)
15.4.4. Imaging Tests
15.4.4.1. X-ray
15.4.4.2. Magnetic Resonance Imaging (MRI)
15.4.4.3. Ultrasound Imaging
15.4.4.4. Computed Tomography (CT) Scanning
15.4.4.5. Others
15.4.5. Others
15.5. Middle East and Africa Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.1. Hospitals
15.5.2. Diagnostics Centres
15.5.3. Ambulatory Surgical Centers
15.5.4. Others
15.6. Middle East and Africa Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.1.1.1. Assays
15.6.1.1.2. Instruments and Systems
15.6.1.1.3. Others
15.6.1.2. Saudi Arabia Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
15.6.1.2.1. Below 30 Years
15.6.1.2.2. 30 Years to 50 Years
15.6.1.2.3. Above 50 Years
15.6.1.3. Saudi Arabia Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
15.6.1.3.1. Serology
15.6.1.3.1.1. Anti-CCP Antibody Test
15.6.1.3.1.2. Rheumatoid Factor (RF)
15.6.1.3.2. Uric Acid
15.6.1.3.3. Acute Phase Reactants
15.6.1.3.3.1. C-reactive Protein (CRP)
15.6.1.3.3.2. Erythrocyte Sedimentation Rate (ESR)
15.6.1.3.4. Imaging Tests
15.6.1.3.4.1. X-ray
15.6.1.3.4.2. Magnetic Resonance Imaging (MRI)
15.6.1.3.4.3. Ultrasound Imaging
15.6.1.3.4.4. Computed Tomography (CT) Scanning
15.6.1.3.4.5. Others
15.6.1.3.5. Others
15.6.1.4. Saudi Arabia Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.4.1. Hospitals
15.6.1.4.2. Diagnostics Centres
15.6.1.4.3. Ambulatory Surgical Centers
15.6.1.4.4. Others
15.6.2. UAE
15.6.2.1. UAE Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offering
15.6.2.1.1. Assays
15.6.2.1.2. Instruments and Systems
15.6.2.1.3. Others
15.6.2.2. UAE Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
15.6.2.2.1. Below 30 Years
15.6.2.2.2. 30 Years to 50 Years
15.6.2.2.3. Above 50 Years
15.6.2.3. UAE Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Test Type
15.6.2.3.1. Serology
15.6.2.3.1.1. Anti-CCP Antibody Test
15.6.2.3.1.2. Rheumatoid Factor (RF)
15.6.2.3.2. Uric Acid
15.6.2.3.3. Acute Phase Reactants
15.6.2.3.3.1. C-reactive Protein (CRP)
15.6.2.3.3.2. Erythrocyte Sedimentation Rate (ESR)
15.6.2.3.4. Imaging Tests
15.6.2.3.4.1. X-ray
15.6.2.3.4.2. Magnetic Resonance Imaging (MRI)
15.6.2.3.4.3. Ultrasound Imaging
15.6.2.3.4.4. Computed Tomography (CT) Scanning
15.6.2.3.4.5. Others
15.6.2.3.5. Others
15.6.2.4. UAE Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End Users
15.6.2.4.1. Hospitals
15.6.2.4.2. Diagnostics Centres
15.6.2.4.3. Ambulatory Surgical Centers
15.6.2.4.4. Others
15.6.3. Egypt
15.6.3.1. Egypt Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offering
15.6.3.1.1. Assays
15.6.3.1.2. Instruments and Systems
15.6.3.1.3. Others
15.6.3.2. Egypt Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Age Group
15.6.3.2.1. Below 30 Years
15.6.3.2.2. 30 Years to 50 Years
15.6.3.2.3. Above 50 Years
15.6.3.3. Egypt Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Test Type
15.6.3.3.1. Serology
15.6.3.3.1.1. Anti-CCP Antibody Test
15.6.3.3.1.2. Rheumatoid Factor (RF)
15.6.3.3.2. Uric Acid
15.6.3.3.3. Acute Phase Reactants
15.6.3.3.3.1. C-reactive Protein (CRP)
15.6.3.3.3.2. Erythrocyte Sedimentation Rate (ESR)
15.6.3.3.4. Imaging Tests
15.6.3.3.4.1. X-ray
15.6.3.3.4.2. Magnetic Resonance Imaging (MRI)
15.6.3.3.4.3. Ultrasound Imaging
15.6.3.3.4.4. Computed Tomography (CT) Scanning
15.6.3.3.4.5. Others
15.6.3.3.5. Others
15.6.3.4. Egypt Rheumatoid Arthritis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End Users
15.6.3.4.1. Hospitals
15.6.3.4.2. Diagnostics Centres
15.6.3.4.3. Ambulatory Surgical Centers
15.6.3.4.4. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.4.1.1. Assays
15.6.4.1.2. Instruments and Systems
15.6.4.1.3. Others
15.6.4.2. Kuwait Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
15.6.4.2.1. Below 30 Years
15.6.4.2.2. 30 Years to 50 Years
15.6.4.2.3. Above 50 Years
15.6.4.3. Kuwait Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
15.6.4.3.1. Serology
15.6.4.3.1.1. Anti-CCP Antibody Test
15.6.4.3.1.2. Rheumatoid Factor (RF)
15.6.4.3.2. Uric Acid
15.6.4.3.3. Acute Phase Reactants
15.6.4.3.3.1. C-reactive Protein (CRP)
15.6.4.3.3.2. Erythrocyte Sedimentation Rate (ESR)
15.6.4.3.4. Imaging Tests
15.6.4.3.4.1. X-ray
15.6.4.3.4.2. Magnetic Resonance Imaging (MRI)
15.6.4.3.4.3. Ultrasound Imaging
15.6.4.3.4.4. Computed Tomography (CT) Scanning
15.6.4.3.4.5. Others
15.6.4.3.5. Others
15.6.4.4. Kuwait Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.4.4.1. Hospitals
15.6.4.4.2. Diagnostics Centres
15.6.4.4.3. Ambulatory Surgical Centers
15.6.4.4.4. Others
15.6.5. South Africa
15.6.5.1. South Africa Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.5.1.1. Assays
15.6.5.1.2. Instruments and Systems
15.6.5.1.3. Others
15.6.5.2. South Africa Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
15.6.5.2.1. Below 30 Years
15.6.5.2.2. 30 Years to 50 Years
15.6.5.2.3. Above 50 Years
15.6.5.3. South Africa Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
15.6.5.3.1. Serology
15.6.5.3.1.1. Anti-CCP Antibody Test
15.6.5.3.1.2. Rheumatoid Factor (RF)
15.6.5.3.2. Uric Acid
15.6.5.3.3. Acute Phase Reactants
15.6.5.3.3.1. C-reactive Protein (CRP)
15.6.5.3.3.2. Erythrocyte Sedimentation Rate (ESR)
15.6.5.3.4. Imaging Tests
15.6.5.3.4.1. X-ray
15.6.5.3.4.2. Magnetic Resonance Imaging (MRI)
15.6.5.3.4.3. Ultrasound Imaging
15.6.5.3.4.4. Computed Tomography (CT) Scanning
15.6.5.3.4.5. Others
15.6.5.3.5. Others
15.6.5.4. South Africa Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.5.4.1. Hospitals
15.6.5.4.2. Diagnostics Centres
15.6.5.4.3. Ambulatory Surgical Centers
15.6.5.4.4. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Rheumatoid
Arthritis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.6.1.1. Assays
15.6.6.1.2. Instruments and Systems
15.6.6.1.3. Others
15.6.6.2. Rest of Middle East & Africa Rheumatoid
Arthritis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
15.6.6.2.1. Below 30 Years
15.6.6.2.2. 30 Years to 50 Years
15.6.6.2.3. Above 50 Years
15.6.6.3. Rest of Middle East & Africa Rheumatoid
Arthritis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
15.6.6.3.1. Serology
15.6.6.3.1.1. Anti-CCP Antibody Test
15.6.6.3.1.2. Rheumatoid Factor (RF)
15.6.6.3.2. Uric Acid
15.6.6.3.3. Acute Phase Reactants
15.6.6.3.3.1. C-reactive Protein (CRP)
15.6.6.3.3.2. Erythrocyte Sedimentation Rate (ESR)
15.6.6.3.4. Imaging Tests
15.6.6.3.4.1. X-ray
15.6.6.3.4.2. Magnetic Resonance Imaging (MRI)
15.6.6.3.4.3. Ultrasound Imaging
15.6.6.3.4.4. Computed Tomography (CT) Scanning
15.6.6.3.4.5. Others
15.6.6.3.5. Others
15.6.6.4. Rest of Middle East & Africa Rheumatoid
Arthritis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals
15.6.6.4.2. Diagnostics Centres
15.6.6.4.3. Ambulatory Surgical Centers
15.6.6.4.4. Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Offering
15.7.3. By Age Group
15.7.4. By Test Type
15.7.5. By End Users
16. Latin America Rheumatoid Arthritis
Diagnostics Market Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn)
16.2. Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
16.2.1. Assays
16.2.2. Instruments and Systems
16.2.3. Others
16.3. Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
16.3.1. Below 30 Years
16.3.2. 30 Years to 50 Years
16.3.3. Above 50 Years
16.4. Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
16.4.1. Serology
16.4.1.1. Anti-CCP Antibody Test
16.4.1.2. Rheumatoid Factor (RF)
16.4.2. Uric Acid
16.4.3. Acute Phase Reactants
16.4.3.1. C-reactive Protein (CRP)
16.4.3.2. Erythrocyte Sedimentation Rate (ESR)
16.4.4. Imaging Tests
16.4.4.1. X-ray
16.4.4.2. Magnetic Resonance Imaging (MRI)
16.4.4.3. Ultrasound Imaging
16.4.4.4. Computed Tomography (CT) Scanning
16.4.4.5. Others
16.4.5. Others
16.5. Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
16.5.1. Hospitals
16.5.2. Diagnostics Centres
16.5.3. Ambulatory Surgical Centers
16.5.4. Others
16.6. Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.1.1.1. Assays
16.6.1.1.2. Instruments and Systems
16.6.1.1.3. Others
16.6.1.2. Brazil Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
16.6.1.2.1. Below 30 Years
16.6.1.2.2. 30 Years to 50 Years
16.6.1.2.3. Above 50 Years
16.6.1.3. Brazil Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
16.6.1.3.1. Serology
16.6.1.3.1.1. Anti-CCP Antibody Test
16.6.1.3.1.2. Rheumatoid Factor (RF)
16.6.1.3.2. Uric Acid
16.6.1.3.3. Acute Phase Reactants
16.6.1.3.3.1. C-reactive Protein (CRP)
16.6.1.3.3.2. Erythrocyte Sedimentation Rate (ESR)
16.6.1.3.4. Imaging Tests
16.6.1.3.4.1. X-ray
16.6.1.3.4.2. Magnetic Resonance Imaging (MRI)
16.6.1.3.4.3. Ultrasound Imaging
16.6.1.3.4.4. Computed Tomography (CT) Scanning
16.6.1.3.4.5. Others
16.6.1.3.5. Others
16.6.1.4. Brazil Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.4.1. Hospitals
16.6.1.4.2. Diagnostics Centres
16.6.1.4.3. Ambulatory Surgical Centers
16.6.1.4.4. Others
16.6.2. Argentina
16.6.2.1. Argentina Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.2.1.1. Assays
16.6.2.1.2. Instruments and Systems
16.6.2.1.3. Others
16.6.2.2. Argentina Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Age Group
16.6.2.2.1. Below 30 Years
16.6.2.2.2. 30 Years to 50 Years
16.6.2.2.3. Above 50 Years
16.6.2.3. Argentina Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Test Type
16.6.2.3.1. Serology
16.6.2.3.1.1. Anti-CCP Antibody Test
16.6.2.3.1.2. Rheumatoid Factor (RF)
16.6.2.3.2. Uric Acid
16.6.2.3.3. Acute Phase Reactants
16.6.2.3.3.1. C-reactive Protein (CRP)
16.6.2.3.3.2. Erythrocyte Sedimentation Rate (ESR)
16.6.2.3.4. Imaging Tests
16.6.2.3.4.1. X-ray
16.6.2.3.4.2. Magnetic Resonance Imaging (MRI)
16.6.2.3.4.3. Ultrasound Imaging
16.6.2.3.4.4. Computed Tomography (CT) Scanning
16.6.2.3.4.5. Others
16.6.2.3.5. Others
16.6.2.4. Argentina Rheumatoid Arthritis Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.2.4.1. Hospitals
16.6.2.4.2. Diagnostics Centres
16.6.2.4.3. Ambulatory Surgical Centers
16.6.2.4.4. Others
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.3.1.1. Assays
16.6.3.1.2. Instruments and Systems
16.6.3.1.3. Others
16.6.3.2. Rest of Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Age Group
16.6.3.2.1. Below 30 Years
16.6.3.2.2. 30 Years to 50 Years
16.6.3.2.3. Above 50 Years
16.6.3.3. Rest of Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Type
16.6.3.3.1. Serology
16.6.3.3.1.1. Anti-CCP Antibody Test
16.6.3.3.1.2. Rheumatoid Factor (RF)
16.6.3.3.2. Uric Acid
16.6.3.3.3. Acute Phase Reactants
16.6.3.3.3.1. C-reactive Protein (CRP)
16.6.3.3.3.2. Erythrocyte Sedimentation Rate (ESR)
16.6.3.3.4. Imaging Tests
16.6.3.3.4.1. X-ray
16.6.3.3.4.2. Magnetic Resonance Imaging (MRI)
16.6.3.3.4.3. Ultrasound Imaging
16.6.3.3.4.4. Computed Tomography (CT) Scanning
16.6.3.3.4.5. Others
16.6.3.3.5. Others
16.6.3.4. Rest of Latin America Rheumatoid Arthritis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals
16.6.3.4.2. Diagnostics Centres
16.6.3.4.3. Ambulatory Surgical Centers
16.6.3.4.4. Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Offering
16.7.3. By Age Group
16.7.4. By Test Type
16.7.5. By End Users
17. Competitive Benchmarking
17.1. Market Share Analysis, 2020
17.2. Global Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1. Abbott Diagnostics
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. AbbVie Inc.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Anamol Laboratories Pvt. Ltd.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Beckman Coulter, Inc.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Bio-Rad Laboratories, Inc.
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. EagleBio
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Euro Diagnostica AB
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. F. Hoffmann-La Roche Ltd.
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Siemens Healthcare GmbH
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Thermo Fisher Scientific Inc.
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
